Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC.ALNY · Entity 3132 | Director | May 20, 2026 | May 22, 2026 |
| PFIZER INCPFE · Entity 2863 | Director | April 26, 2018 | April 30, 2018 |
| Rani Therapeutics Holdings, Inc.RANI · Entity 6642 | Director | May 28, 2026 | June 01, 2026 |
| Seres Therapeutics, Inc.MCRB · Entity 7191 | Director | July 08, 2026 | July 10, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ALNYLAM PHARMACEUTICALS, INC.
Report date May 20, 2026 · Filed May 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,582 |
Reported balance
After 2026-05-20 transaction · row 1
1 source rowRow 1 · 2026-05-20 · Grant · Acquired 671 · Balance 1,582 F1: These shares are represented by restricted stock units (RSUs) granted under the Second Amended and Restated 2018 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock. The RSUs will vest in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $298.48 · Expires 2036-05-20 | Direct | 1,441 |
Reported balance
After 2026-05-20 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-05-20 · Grant · Acquired 1,441 · Balance 1,441 F3: The stock option will vest in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date. |
| Common StockSEC Table I · non-derivative | Indirectby Trust | 3,500 |
Reported balance
Holding disclosure · report date 2026-05-20 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 3,500 F2: The shares of ALNY common stock are held in a trust, of which the reporting person's spouse is the trustee. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares are represented by restricted stock units (RSUs) granted under the Second Amended and Restated 2018 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock. The RSUs will vest in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date.
F2: The shares of ALNY common stock are held in a trust, of which the reporting person's spouse is the trustee.
F3: The stock option will vest in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date.
PFIZER INC
Report date April 26, 2018 · Filed April 30, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Phantom Stock UnitsSEC Table II · derivative / convertible security | Direct | 47,345.774 |
Reported balance
After 2018-04-26 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-04-26 · Grant · Acquired 5,223.881 · Balance 47,345.774 F1: Each unit represents one phantom share of common stock. F2: Granted pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors. F3: These units represent deferred director's compensation that are settled in cash or common stock at the director's election, following the reporting person's retirement from the Board of Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: Each unit represents one phantom share of common stock.
F2: Granted pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors.
F3: These units represent deferred director's compensation that are settled in cash or common stock at the director's election, following the reporting person's retirement from the Board of Directors.
Rani Therapeutics Holdings, Inc.
Report date May 28, 2026 · Filed June 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.95 · Expires 2036-05-27 | Direct | 123,600 |
Reported balance
After 2026-05-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-28 · Grant · Acquired 123,600 · Balance 123,600 F1: The shares subject to the option vest in full on the first anniversary of the date of grant, subject to the Reporting Person's Continuous Service (as defined in the Company's 2021 Equity Incentive Plan (the "2021 Plan")) through such vesting date; provided that, if earlier, the shares subject to the option will vest in full upon the occurrence of either of the following events: the Company's next annual stockholder meeting or a Change in Control (as defined in the 2021 Plan), each subject to the Reporting Person's Continuous Service through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option vest in full on the first anniversary of the date of grant, subject to the Reporting Person's Continuous Service (as defined in the Company's 2021 Equity Incentive Plan (the "2021 Plan")) through such vesting date; provided that, if earlier, the shares subject to the option will vest in full upon the occurrence of either of the following events: the Company's next annual stockholder meeting or a Change in Control (as defined in the 2021 Plan), each subject to the Reporting Person's Continuous Service through such date.
Seres Therapeutics, Inc.
Report date July 08, 2026 · Filed July 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.14 · Expires 2036-07-07 | Direct | 6,500 |
Reported balance
After 2026-07-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-07-08 · Grant · Acquired 6,500 · Balance 6,500 F1: The option vests and becomes exercisable on the earlier to occur of (i) July 8, 2027 or (ii) the day immediately prior to the first annual meeting of the Company's stockholders occurring after July 8, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests and becomes exercisable on the earlier to occur of (i) July 8, 2027 or (ii) the day immediately prior to the first annual meeting of the Company's stockholders occurring after July 8, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 08, 2026 Filed Jul 10, 2026 16:15 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantStock Option (right to buy) · Derivative | 6,500 | $0.00 Strike: $7.14 | $0.00 |
DisclosureSEC source: 0001193125-26-300918 · ownership.xml · derivative · entry 1 Ausiello Dennis A · CIK 0001381994 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,500 Underlying: Common Stock · 6,500 shares Expires 2036-07-07 F1 · derivative.exercise_date: The option vests and becomes exercisable on the earlier to occur of (i) July 8, 2027 or (ii) the day immediately prior to the first annual meeting of the Company's stockholders occurring after July 8, 2026. Read SEC document |
| July 01, 2026 Filed Jul 2, 2026 22:05 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantStock Option (right to buy) · Derivative | 7,508 | $0.00 Strike: $7.94 | $0.00 |
DisclosureSEC source: 0001193125-26-295059 · ownership.xml · derivative · entry 1 Ausiello Dennis A · CIK 0001381994 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,508 Underlying: Common Stock · 7,508 shares Expires 2036-07-01 F1 · derivative.exercise_date: The option vests and becomes exercisable in four equal quarterly installments occurring on October 1, 2026, January 1, 2027, April 1, 2027, and July 1, 2027, provided that if the issuer's 2027 annual meeting of stockholders occurs before July 1, 2027, the final quarterly vesting installment will vest on the day immediately prior to the date of such annual meeting, in each case, subject to the reporting person continuing in service on the Board as a non-employee director through the applicable vesting date. Read SEC document |
| May 28, 2026 Filed Jun 1, 2026 20:08 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | GrantDirector Stock Option (Right to Buy) · Derivative | 123,600 | $0.00 Strike: $0.95 | $0.00 |
DisclosureSEC source: 0001381994-26-000003 · ownership.xml · derivative · entry 1 Ausiello Dennis A · CIK 0001381994 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 123,600 Underlying: Class A Common Stock · 123,600 shares Expires 2036-05-27 F1 · derivative.exercise_date: The shares subject to the option vest in full on the first anniversary of the date of grant, subject to the Reporting Person's Continuous Service (as defined in the Company's 2021 Equity Incentive Plan (the "2021 Plan")) through such vesting date; provided that, if earlier, the shares subject to the option will vest in full upon the occurrence of either of the following events: the Company's next annual stockholder meeting or a Change in Control (as defined in the 2021 Plan), each subject to the Reporting Person's Continuous Service through such date. Read SEC document |
| May 20, 2026 Filed May 22, 2026 20:06 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantStock Option (Right to Buy) · Derivative | 1,441 | $0.00 Strike: $298.48 | $0.00 |
DisclosureSEC source: 0001178670-26-000035 · form4.xml · derivative · entry 3 Ausiello Dennis A · CIK 0001381994 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,441 Underlying: Common Stock · 1,441 shares Expires 2036-05-20 F3 · derivative.exercise_date: The stock option will vest in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date. Read SEC document |
| May 20, 2026 Filed May 22, 2026 20:06 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantCommon Stock | 671 | $0.00 | $0.00 |
DisclosureSEC source: 0001178670-26-000035 · form4.xml · nonDerivative · entry 1 Ausiello Dennis A · CIK 0001381994 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,582 F1 · shares: These shares are represented by restricted stock units (RSUs) granted under the Second Amended and Restated 2018 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock. The RSUs will vest in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date. Read SEC document |
| August 14, 2025 Filed Aug 15, 2025 20:05 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionStock Option (right to buy) · Derivative | 3,454 | $0.00 Strike: $189.87 | $0.00 |
DisclosureSEC source: 0001735276-25-000079 · edgardoc.xml · derivative · entry 24 Ausiello Dennis A · CIK 0001381994 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,454 shares Expires 2033-05-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on May 15, 2025. F19 · derivative.exercise_date: The stock option was fully vested as of May 18, 2024. Read SEC document |
| August 14, 2025 Filed Aug 15, 2025 20:05 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionStock Option (right to buy) · Derivative | 4,032 | $0.00 Strike: $171.95 | $0.00 |
DisclosureSEC source: 0001735276-25-000079 · edgardoc.xml · derivative · entry 23 Ausiello Dennis A · CIK 0001381994 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,032 shares Expires 2031-07-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on May 15, 2025. F18 · derivative.exercise_date: The stock option was fully vested as of July 15, 2022. Read SEC document |
| August 14, 2025 Filed Aug 15, 2025 20:05 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionStock Option (right to buy) · Derivative | 5,228 | $0.00 Strike: $151.22 | $0.00 |
DisclosureSEC source: 0001735276-25-000079 · edgardoc.xml · derivative · entry 22 Ausiello Dennis A · CIK 0001381994 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,228 shares Expires 2034-05-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on May 15, 2025. F17 · derivative.exercise_date: The stock option was fully vested as of May 16, 2025. Read SEC document |
| August 14, 2025 Filed Aug 15, 2025 20:05 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionStock Option (right to buy) · Derivative | 4,581 | $0.00 Strike: $148.77 | $0.00 |
DisclosureSEC source: 0001735276-25-000079 · edgardoc.xml · derivative · entry 21 Ausiello Dennis A · CIK 0001381994 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,581 shares Expires 2030-07-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on May 15, 2025. F16 · derivative.exercise_date: The stock option was fully vested as of July 1, 2021. Read SEC document |
| August 14, 2025 Filed Aug 15, 2025 20:05 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionStock Option (right to buy) · Derivative | 5,153 | $0.00 Strike: $128.31 | $0.00 |
DisclosureSEC source: 0001735276-25-000079 · edgardoc.xml · derivative · entry 20 Ausiello Dennis A · CIK 0001381994 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,153 shares Expires 2032-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on May 15, 2025. F15 · derivative.exercise_date: The stock option was fully vested as of May 18, 2023. Read SEC document |
| August 14, 2025 Filed Aug 15, 2025 20:05 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionStock Option (right to buy) · Derivative | 9,000 | $0.00 Strike: $72.01 | $0.00 |
DisclosureSEC source: 0001735276-25-000079 · edgardoc.xml · derivative · entry 19 Ausiello Dennis A · CIK 0001381994 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,000 shares Expires 2029-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on May 15, 2025. F14 · derivative.exercise_date: The stock option was fully vested as of July 1, 2020. Read SEC document |
| August 14, 2025 Filed Aug 15, 2025 20:05 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 641 | $442.66 | $283,745.06 |
DisclosureSEC source: 0001735276-25-000079 · edgardoc.xml · nonDerivative · entry 17 Ausiello Dennis A · CIK 0001381994 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 911 F1 · kind: All transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on May 15, 2025. F12 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $442.44 to $443.10 The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| August 14, 2025 Filed Aug 15, 2025 20:05 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 1,205 | $441.88 | $532,465.40 |
DisclosureSEC source: 0001735276-25-000079 · edgardoc.xml · nonDerivative · entry 16 Ausiello Dennis A · CIK 0001381994 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,552 F1 · kind: All transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on May 15, 2025. F11 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $441.41 to $442.11 The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| August 14, 2025 Filed Aug 15, 2025 20:05 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 1,238 | $440.54 | $545,388.52 |
DisclosureSEC source: 0001735276-25-000079 · edgardoc.xml · nonDerivative · entry 15 Ausiello Dennis A · CIK 0001381994 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,757 F1 · kind: All transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on May 15, 2025. F10 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $440.24 to $440.93 The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| August 14, 2025 Filed Aug 15, 2025 20:05 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 5,302 | $439.27 | $2,329,009.54 |
DisclosureSEC source: 0001735276-25-000079 · edgardoc.xml · nonDerivative · entry 14 Ausiello Dennis A · CIK 0001381994 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,995 F1 · kind: All transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on May 15, 2025. F9 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $438.91 to $439.89 The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| August 14, 2025 Filed Aug 15, 2025 20:05 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 2,086 | $438.34 | $914,377.24 |
DisclosureSEC source: 0001735276-25-000079 · edgardoc.xml · nonDerivative · entry 13 Ausiello Dennis A · CIK 0001381994 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,297 F1 · kind: All transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on May 15, 2025. F8 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $437.85 to $438.71 The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| August 14, 2025 Filed Aug 15, 2025 20:05 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 1,922 | $437.56 | $840,990.32 |
DisclosureSEC source: 0001735276-25-000079 · edgardoc.xml · nonDerivative · entry 12 Ausiello Dennis A · CIK 0001381994 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,383 F1 · kind: All transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on May 15, 2025. F7 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $436.84 to $437.83 The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| August 14, 2025 Filed Aug 15, 2025 20:05 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 5,358 | $436.00 | $2,336,088.00 |
DisclosureSEC source: 0001735276-25-000079 · edgardoc.xml · nonDerivative · entry 11 Ausiello Dennis A · CIK 0001381994 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,305 F1 · kind: All transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on May 15, 2025. F6 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $435.79 to $436.35 The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| August 14, 2025 Filed Aug 15, 2025 20:05 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 7,675 | $435.40 | $3,341,695.00 |
DisclosureSEC source: 0001735276-25-000079 · edgardoc.xml · nonDerivative · entry 10 Ausiello Dennis A · CIK 0001381994 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,663 F1 · kind: All transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on May 15, 2025. F5 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $434.69 to $435.66. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| August 14, 2025 Filed Aug 15, 2025 20:05 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 2,098 | $434.50 | $911,581.00 |
DisclosureSEC source: 0001735276-25-000079 · edgardoc.xml · nonDerivative · entry 9 Ausiello Dennis A · CIK 0001381994 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,338 F1 · kind: All transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on May 15, 2025. F4 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $433.59 to $434.56. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| August 14, 2025 Filed Aug 15, 2025 20:05 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 1,938 | $432.94 | $839,037.72 |
DisclosureSEC source: 0001735276-25-000079 · edgardoc.xml · nonDerivative · entry 8 Ausiello Dennis A · CIK 0001381994 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,436 F1 · kind: All transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on May 15, 2025. F3 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $432.10 to $433.06. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| August 14, 2025 Filed Aug 15, 2025 20:05 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 1,985 | $430.81 | $855,157.85 |
DisclosureSEC source: 0001735276-25-000079 · edgardoc.xml · nonDerivative · entry 7 Ausiello Dennis A · CIK 0001381994 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,374 F1 · kind: All transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on May 15, 2025. F2 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $430.39 to $431.24. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| August 14, 2025 Filed Aug 15, 2025 20:05 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 3,454 | $189.87 | $655,810.98 |
DisclosureSEC source: 0001735276-25-000079 · edgardoc.xml · nonDerivative · entry 6 Ausiello Dennis A · CIK 0001381994 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,359 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on May 15, 2025. Read SEC document |
| August 14, 2025 Filed Aug 15, 2025 20:05 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 4,032 | $171.95 | $693,302.40 |
DisclosureSEC source: 0001735276-25-000079 · edgardoc.xml · nonDerivative · entry 5 Ausiello Dennis A · CIK 0001381994 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,905 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on May 15, 2025. Read SEC document |
| August 14, 2025 Filed Aug 15, 2025 20:05 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 5,228 | $151.22 | $790,578.16 |
DisclosureSEC source: 0001735276-25-000079 · edgardoc.xml · nonDerivative · entry 4 Ausiello Dennis A · CIK 0001381994 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,873 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on May 15, 2025. Read SEC document |
| August 14, 2025 Filed Aug 15, 2025 20:05 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 4,581 | $148.77 | $681,515.37 |
DisclosureSEC source: 0001735276-25-000079 · edgardoc.xml · nonDerivative · entry 3 Ausiello Dennis A · CIK 0001381994 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,645 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on May 15, 2025. Read SEC document |
| August 14, 2025 Filed Aug 15, 2025 20:05 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 5,153 | $128.31 | $661,181.43 |
DisclosureSEC source: 0001735276-25-000079 · edgardoc.xml · nonDerivative · entry 2 Ausiello Dennis A · CIK 0001381994 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,064 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on May 15, 2025. Read SEC document |
| August 14, 2025 Filed Aug 15, 2025 20:05 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 9,000 | $72.01 | $648,090.00 |
DisclosureSEC source: 0001735276-25-000079 · edgardoc.xml · nonDerivative · entry 1 Ausiello Dennis A · CIK 0001381994 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,911 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on May 15, 2025. Read SEC document |
| July 01, 2025 Filed Jul 2, 2025 21:58 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantStock Option (right to buy) · Derivative | 6,452 | $0.00 Strike: $10.71 | $0.00 |
DisclosureSEC source: 0000950170-25-093311 · ownership.xml · derivative · entry 1 Ausiello Dennis A · CIK 0001381994 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,452 Underlying: Common Stock · 6,452 shares Expires 2035-07-01 F1 · derivative.exercise_date: The option vests and becomes exercisable in four equal quarterly installments occurring on October 1, 2025, January 1, 2026, April 1, 2026, and July 1, 2026, provided that if the issuer's 2026 annual meeting of stockholders occurs before July 1, 2026, the final quarterly vesting installment will vest on the day immediately prior to the date of such annual meeting, in each case, subject to the reporting person continuing in service on the Board as a non-employee director through the applicable vesting date. Read SEC document |
| May 28, 2025 Filed May 30, 2025 21:50 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | GrantDirector Stock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $0.62 | $0.00 |
DisclosureSEC source: 0001415889-25-015034 · form4-05302025_090532.xml · derivative · entry 1 Ausiello Dennis A · CIK 0001381994 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Class A Common Stock · 50,000 shares Expires 2035-05-27 F1 · derivative.exercise_date: The shares subject to the option vest in full on the first anniversary of the date of grant, subject to the recipient's Continuous Service (as defined in the Company's 2021 Equity Incentive Plan) through such vesting date; provided that, if earlier, the shares subject to the option will vest in full upon the occurrence of either of the following events: the Company's next annual stockholder meeting or a Change in Control (as defined in the Company's 2021 Equity Incentive Plan). Read SEC document |
| May 08, 2025 Filed May 12, 2025 20:07 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantStock Option (right to buy) · Derivative | 1,558 | $0.00 Strike: $258.35 | $0.00 |
DisclosureSEC source: 0001735276-25-000068 · edgardoc.xml · derivative · entry 3 Ausiello Dennis A · CIK 0001381994 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,558 Underlying: Common Stock · 1,558 shares Expires 2035-05-08 F3 · derivative.exercise_date: The stock option vests in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date. Read SEC document |
| May 08, 2025 Filed May 12, 2025 20:07 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantCommon Stock | 775 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-25-000068 · edgardoc.xml · nonDerivative · entry 1 Ausiello Dennis A · CIK 0001381994 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 911 F1 · shares: These shares are represented by restricted stock units (RSUs) granted under the Amended and Restated 2018 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock. The RSUs will vest in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date. Read SEC document |
| April 10, 2025 Filed Apr 11, 2025 20:05 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $0.58 | $0.00 |
DisclosureSEC source: 0000950170-25-053245 · ownership.xml · derivative · entry 1 Ausiello Dennis A · CIK 0001381994 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2035-04-09 F1 · derivative.exercise_date: The option vests in full on the earlier of April 10, 2026 or the day immediately prior to the company's 2026 annual meeting of shareholders. Read SEC document |
| December 16, 2024 Filed Dec 17, 2024 22:00 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | GrantStock Option (Right to Buy) · Derivative | 15,423 | Not disclosed Strike: $9.44 | Not disclosed |
DisclosureSEC source: 0000950170-24-137321 · ownership.xml · derivative · entry 4 Ausiello Dennis A · CIK 0001381994 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,317 Underlying: Class A Common Stock · 15,423 shares Expires 2031-07-28 F3 · price: On December 16, 2024, the exercise price of the stock options has been amended to increase the exercise price to $9.44 per share. There is no change to the expiration dates or the vesting schedule of the options. F2 · derivative.exercise_date: The shares subject to the option vested as follows: 1/36th of the shares subject to the option vested monthly over three years from June 17, 2021. Read SEC document |
| December 16, 2024 Filed Dec 17, 2024 22:00 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | Disposition to issuerStock Option (Right to Buy) · Derivative | 15,423 | Not disclosed Strike: $2.84 | Not disclosed |
DisclosureSEC source: 0000950170-24-137321 · ownership.xml · derivative · entry 3 Ausiello Dennis A · CIK 0001381994 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 15,423 shares Expires 2031-07-28 F3 · price: On December 16, 2024, the exercise price of the stock options has been amended to increase the exercise price to $9.44 per share. There is no change to the expiration dates or the vesting schedule of the options. F2 · derivative.exercise_date: The shares subject to the option vested as follows: 1/36th of the shares subject to the option vested monthly over three years from June 17, 2021. Read SEC document |
| December 16, 2024 Filed Dec 17, 2024 22:00 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | GrantStock Option (Right to Buy) · Derivative | 101,276 | Not disclosed Strike: $4.11 | Not disclosed |
DisclosureSEC source: 0000950170-24-137321 · ownership.xml · derivative · entry 2 Ausiello Dennis A · CIK 0001381994 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 101,276 Underlying: Class A Common Stock · 101,276 shares Expires 2033-05-24 F1 · price: On December 16, 2024, the exercise price of the stock options has been amended to increase the exercise price to $4.11 per share. There is no change to the expiration dates or the vesting schedule of the options. Read SEC document |
| December 16, 2024 Filed Dec 17, 2024 22:00 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | Disposition to issuerStock Option (Right to Buy) · Derivative | 101,276 | Not disclosed Strike: $2.84 | Not disclosed |
DisclosureSEC source: 0000950170-24-137321 · ownership.xml · derivative · entry 1 Ausiello Dennis A · CIK 0001381994 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 101,276 shares Expires 2033-05-24 F1 · price: On December 16, 2024, the exercise price of the stock options has been amended to increase the exercise price to $4.11 per share. There is no change to the expiration dates or the vesting schedule of the options. Read SEC document |
| August 06, 2024 Filed Aug 8, 2024 20:10 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionStock Option (right to buy) · Derivative | 11,250 | $0.00 Strike: $131.21 | $0.00 |
DisclosureSEC source: 0001735276-24-000080 · edgardoc.xml · derivative · entry 12 Ausiello Dennis A · CIK 0001381994 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,250 shares Expires 2025-06-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on May 3, 2024. F11 · derivative.exercise_date: This stock option was fully vested and exercisable as of June 1, 2016. Read SEC document |
| August 06, 2024 Filed Aug 8, 2024 20:10 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionStock Option (right to buy) · Derivative | 9,000 | $0.00 Strike: $105.26 | $0.00 |
DisclosureSEC source: 0001735276-24-000080 · edgardoc.xml · derivative · entry 11 Ausiello Dennis A · CIK 0001381994 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,000 shares Expires 2028-06-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on May 3, 2024. F10 · derivative.exercise_date: This stock option was fully vested and exercisable as of June 20, 2019. Read SEC document |
| August 06, 2024 Filed Aug 8, 2024 20:10 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 262 | $266.45 | $69,809.90 |
DisclosureSEC source: 0001735276-24-000080 · edgardoc.xml · nonDerivative · entry 9 Ausiello Dennis A · CIK 0001381994 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 136 F1 · kind: All transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on May 3, 2024. F8 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $266.39 to $266.66. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| August 06, 2024 Filed Aug 8, 2024 20:10 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 632 | $264.95 | $167,448.40 |
DisclosureSEC source: 0001735276-24-000080 · edgardoc.xml · nonDerivative · entry 8 Ausiello Dennis A · CIK 0001381994 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 398 F1 · kind: All transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on May 3, 2024. F7 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $264.37 to $265.09. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| August 06, 2024 Filed Aug 8, 2024 20:10 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 3,408 | $263.72 | $898,757.76 |
DisclosureSEC source: 0001735276-24-000080 · edgardoc.xml · nonDerivative · entry 7 Ausiello Dennis A · CIK 0001381994 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,030 F1 · kind: All transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on May 3, 2024. F6 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $263.29 to $264.20. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| August 06, 2024 Filed Aug 8, 2024 20:10 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 4,367 | $262.79 | $1,147,603.93 |
DisclosureSEC source: 0001735276-24-000080 · edgardoc.xml · nonDerivative · entry 6 Ausiello Dennis A · CIK 0001381994 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,438 F1 · kind: All transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on May 3, 2024. F5 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $262.26 to $263.26. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| August 06, 2024 Filed Aug 8, 2024 20:10 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 6,212 | $261.63 | $1,625,245.56 |
DisclosureSEC source: 0001735276-24-000080 · edgardoc.xml · nonDerivative · entry 5 Ausiello Dennis A · CIK 0001381994 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,805 F1 · kind: All transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on May 3, 2024. F4 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $261.21 to $262.21. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| August 06, 2024 Filed Aug 8, 2024 20:10 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 3,742 | $260.40 | $974,416.80 |
DisclosureSEC source: 0001735276-24-000080 · edgardoc.xml · nonDerivative · entry 4 Ausiello Dennis A · CIK 0001381994 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,017 F1 · kind: All transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on May 3, 2024. F3 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $259.87 to $260.84. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| August 06, 2024 Filed Aug 8, 2024 20:10 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 1,627 | $259.56 | $422,304.12 |
DisclosureSEC source: 0001735276-24-000080 · edgardoc.xml · nonDerivative · entry 3 Ausiello Dennis A · CIK 0001381994 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,759 F1 · kind: All transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on May 3, 2024. F2 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $258.85 to $259.85. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| August 06, 2024 Filed Aug 8, 2024 20:10 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 9,000 | $105.26 | $947,340.00 |
DisclosureSEC source: 0001735276-24-000080 · edgardoc.xml · nonDerivative · entry 2 Ausiello Dennis A · CIK 0001381994 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,386 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on May 3, 2024. Read SEC document |
| August 06, 2024 Filed Aug 8, 2024 20:10 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 11,250 | $131.21 | $1,476,112.50 |
DisclosureSEC source: 0001735276-24-000080 · edgardoc.xml · nonDerivative · entry 1 Ausiello Dennis A · CIK 0001381994 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,386 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on May 3, 2024. Read SEC document |
| July 01, 2024 Filed Jul 3, 2024 20:15 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantStock Option (right to buy) · Derivative | 64,564 | $0.00 Strike: $0.72 | $0.00 |
DisclosureSEC source: 0000950170-24-081527 · ownership.xml · derivative · entry 1 Ausiello Dennis A · CIK 0001381994 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,564 Underlying: Common Stock · 64,564 shares Expires 2034-06-30 F1 · derivative.exercise_date: The option vests and becomes exercisable in four equal quarterly installments occurring on October 1, 2024, January 1, 2025, April 1, 2025 and July 1, 2025, provided that if the Company's 2025 annual meeting of stockholders occurs before July 1, 2025, the final quarterly vesting installment will vest on the day immediately prior to the date of such annual meeting, in each case, subject to the reporting person continuing in service on the Board as a non-employee director through the applicable vesting date. Read SEC document |
| May 29, 2024 Filed May 30, 2024 20:10 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $5.00 | $0.00 |
DisclosureSEC source: 0000950170-24-066586 · ownership.xml · derivative · entry 1 Ausiello Dennis A · CIK 0001381994 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Class A Common Stock · 50,000 shares Expires 2034-05-28 F1 · derivative.exercise_date: The shares subject to the option vest in full on the first anniversary of the date of grant, subject to the recipient's Continuous Service (as defined in the Company's 2021 Equity Incentive Plan) through such vesting date; provided that, if earlier, the shares subject to the option will vest in full upon the occurrence of either of the following events: the Company's next annual stockholder meeting or a Change in Control (as defined in the Company's 2021 Equity Incentive Plan). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.